Compare Cadence Design Systems Inc (CDNS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Novo Nordisk A/S — how do they compare? Cadence Design Systems Inc trades at $326.82 (market cap $90.20B), while Novo Nordisk A/S trades at $46.04 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Cadence Design Systems Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Cadence Design Systems Inc pays none. Which is the better fit depends on your goals.
| CDNS | NVO | |
|---|---|---|
Market Cap | $90.20B | $207.85B |
Sector | Technology | Health |
52-Week High | $416.39 | $63.98 |
52-Week Low | $265.66 | $35.29 |
Enterprise Value | $91.41B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $331.91, down 2.16% amid a bearish technical signal, though it remains supported by strong fundamentals. The company reported Q2 2026 earnings that beat estimates, with revenue growth of 24.2% driven by AI demand, and raised its full-year outlook. Analyst consensus is strongly bullish with an average price target of $415.11, representing 25% upside potential from current levels.
The stock offers compelling growth prospects from AI-driven semiconductor design demand, with record backlog of $8.1 billion supporting future revenue visibility. Key risks include high valuation multiples (P/E 65.12) and potential semiconductor cycle volatility. Institutional ownership remains strong with recent position increases by major funds like Amundi.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
